Treatment Rate for Major Depressive Disorder in China: a Meta-Analysis of Epidemiological Studies

被引:15
|
作者
Qi, Han [1 ,2 ,3 ]
Zong, Qian-Qian [4 ]
Lok, Grace K. I. [5 ]
Rao, Wen-Wang [5 ]
An, Feng-Rong [1 ,2 ,3 ]
Ungvari, Gabor S. [6 ,7 ]
Balbuena, Lloyd [8 ]
Zhang, Qing-E [1 ,2 ,3 ]
Xiang, Yu-Tao [5 ]
机构
[1] Capital Med Univ, Natl Clin Res Ctr Mental Disorders, Beijing, Peoples R China
[2] Capital Med Univ, Beijing Key Lab Mental Disorders, Beijing Anding Hosp, Beijing, Peoples R China
[3] Capital Med Univ, Adv Innovat Ctr Human Brain Protect, Beijing, Peoples R China
[4] Capital Med Univ, Sch Nursing, Beijing, Peoples R China
[5] Univ Macau, Fac Hlth Sci, Inst Translat Med, Unit Psychiat, 3-F,Bldg E12,Ave Univ, Taipa, Macao, Peoples R China
[6] Univ Notre Dame Australia, Fremantle, WA, Australia
[7] Univ Western Australia, Sch Med, Div Psychiat, Perth, WA, Australia
[8] Univ Saskatchewan, Dept Psychiat, Saskatoon, SK, Canada
关键词
Major depressive disorder; Treatment rate; Meta-analysis; China; MENTAL-HEALTH-SERVICES; PREVALENCE; DISEASE; BURDEN; SCHIZOPHRENIA; COMORBIDITY; CHALLENGES; COUNTRIES; SYMPTOMS; ANXIETY;
D O I
10.1007/s11126-019-09666-9
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Major depressive disorder (MDD) is a common psychiatric disorder in China, but its reported treatment rate varies largely across different studies. The objective of this meta-analysis was to determine the pooled treatment rate for people with MDD in China and its associated factors. Both English (PubMed, Cochrane Library, PsycINFO, Web of Science) and Chinese (Chinese National Knowledge Infrastructure, WanFang and SinoMed) databases were searched from their commencement date to November 13, 2018. Epidemiological studies that reported the treatment rate of MDD were included and synthesized using a random effects model. Fifteen studies covering 609,054 participants were included. The pooled treatment rate for MDD in China was 19.5% (95% CI: 10.7%-28.4%). Among the 15 studies, 9 reported the number of patients who received treatments in psychiatric hospitals with a pooled treatment rate of 5.2% (95% CI: 2.8%-7.5%). Meta-regression found that study quality (beta = 0.131, P = 0.028) and male gender (beta = 0.006, P = 0.039) were significantly associated with a higher treatment rate for MDD. In China, the treatment rate for MDD, particularly in psychiatric hospitals, was low. Effective public education and increasing access to mental health services will probably increase the number of people seeking and receiving treatment.
引用
收藏
页码:883 / 895
页数:13
相关论文
共 50 条
  • [1] Treatment Rate for Major Depressive Disorder in China: a Meta-Analysis of Epidemiological Studies
    Han Qi
    Qian-Qian Zong
    Grace K. I. Lok
    Wen-Wang Rao
    Feng-Rong An
    Gabor S. Ungvari
    Lloyd Balbuena
    Qing-E Zhang
    Yu-Tao Xiang
    [J]. Psychiatric Quarterly, 2019, 90 : 883 - 895
  • [2] Treatment Rate of Schizophrenia in China: a Meta-Analysis of Epidemiological Studies
    Han Qi
    Qian-Qian Zong
    Feng-Rong An
    Ling Zhang
    Gabor S. Ungvari
    Kang Sim
    Seon-Cheol Park
    Yu-Tao Xiang
    [J]. Psychiatric Quarterly, 2020, 91 : 863 - 875
  • [3] Treatment Rate of Schizophrenia in China: a Meta-Analysis of Epidemiological Studies
    Qi, Han
    Zong, Qian-Qian
    An, Feng-Rong
    Zhang, Ling
    Ungvari, Gabor S.
    Sim, Kang
    Park, Seon-Cheol
    Xiang, Yu-Tao
    [J]. PSYCHIATRIC QUARTERLY, 2020, 91 (03) : 863 - 875
  • [4] Meta-analysis of genetic studies in major depressive disorder
    Cecile, A.
    Janssens, J. W.
    Leon, Sandra Lopez
    Ladd, Angela M. Gonzalez-Zuloeta
    Del-Favero, Jurgen
    Claes, Stephan
    Oostra, Ben A.
    [J]. AMERICAN JOURNAL OF MEDICAL GENETICS PART B-NEUROPSYCHIATRIC GENETICS, 2006, 141B (07) : 693 - 693
  • [5] Escitalopram in the treatment of major depressive disorder: A meta-analysis
    Kennedy, Sidney H.
    Andersen, Henning F.
    Thase, Michael E.
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2009, 25 (01) : 161 - 175
  • [6] Prevalence of comorbid major depressive disorder in Type 2 diabetes: a meta-analysis of comparative and epidemiological studies
    Wang, F.
    Wang, S.
    Zong, Q-Q
    Zhang, Q.
    Ng, C. H.
    Ungvari, G. S.
    Xiang, Y-T
    [J]. DIABETIC MEDICINE, 2019, 36 (08) : 961 - 969
  • [7] The effect of treatment as usual on major depressive disorder: A meta-analysis
    Kolovos, Spyros
    van Tulder, Maurits W.
    Cuijpers, Pim
    Prigent, Amelie
    Chevreul, Karine
    Riper, Heleen
    Bosmans, Judith E.
    [J]. JOURNAL OF AFFECTIVE DISORDERS, 2017, 210 : 72 - 81
  • [8] Global prevalence of major depressive disorder in LGBTQ plus samples: A systematic review and meta-analysis of epidemiological studies
    Cai, Hong
    Chen, Pan
    Zhang, Qinge
    Lam, Mei Ieng
    Si, Tong Leong
    Liu, Yu -Fei
    Zheng, Wan-Ying
    Su, Zhaohui
    Cheung, Teris
    Jackson, Todd
    Ungvari, Gabor S.
    Ren, Zhihong
    Li, Xinyue
    Li, Xiao-Hong
    Xiang, Yu -Tao
    [J]. JOURNAL OF AFFECTIVE DISORDERS, 2024, 360 : 249 - 258
  • [9] A Meta-Analysis of Functional Neuroimaging Studies of Major Depressive Disorder in Youth
    Zamora, Gladys
    Baten, Caitlin
    Klassen, Amanda M.
    Shepherd, Jonah H.
    Pritchard, Elizabeth
    Saravia, Sarah
    Ali, Zulaikha
    Jordan, Jillian
    Kahlon, Saneh K.
    Maly, Grace
    Duran, Marisol
    Santos, Shay
    Kaur, Anmol
    Saini, Aran
    Nimarko, Akua F.
    Hedges, Dawson W.
    Hamilton, Paul
    Gotlib, Ian H.
    Sacchet, Matthew D.
    Miller, Chris H.
    [J]. BIOLOGICAL PSYCHIATRY, 2023, 93 (09) : S280 - S280
  • [10] Efficacy and safety of zuranolone in the treatment of major depressive disorder: a meta-analysis
    Wang, Shuyu
    Zhang, Wenxing
    Liu, Zhang
    Zhang, Tian
    Wang, Yi
    Li, Weihong
    [J]. FRONTIERS IN NEUROSCIENCE, 2024, 17